+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 55 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
C

Actively Recruiting

Researchers are evaluating two forms of buprenorphine treatment for Veterans with moderate to severe opioid use disorder OUD. The study compares a long-acting injectable buprenorphine given every 28 days with the standard daily sublingual buprenorphine. This open-label, randomized trial involves 952 Veterans over a 7-year recruitment period and follows them actively for 52 weeks, with additional passive follow-up for up to 10 years. The study also examines effects on substance use, overdose rates, infectious disease status, psychiatric symptoms, housing, dental health, and cost-effectiveness. Participants are first inducted on daily sublingual buprenorphine following SAMHSA guidelines. After reaching a target dose between 4 and 32 mg within 45 days, they are randomized 11 to either continue daily sublingual doses or receive a monthly injectable buprenorphine dose of 300 mg or 100 mg if needed. Study visits occur weekly for the first month, then every two weeks up to week 52, with medication management provided at each visit. Both treatments are administered under clinical supervision with dosing adjustments as needed. Throughout the study, participants complete self-reported opioid use and provide urine samples biweekly. Researchers collect data on retention in treatment, opioid abstinence, overdose events, infectious disease testing, healthcare utilization, craving, psychiatric symptoms, criminal justice involvement, and dental quality of life. After one year of active participation, administrative records are reviewed for ongoing outcomes for up to 10 years. This comprehensive monitoring aims to provide long-term insights into treatment effectiveness and patient well-being.

Age: 18Years +All GendersPhase 4
25 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying how aging affects the immediate impact of THC on thinking skills, feelings, and heart functions in adults over 21 years old. The study also looks at age-related differences in brain processing and how the body breaks down THC. This research aims to better understand the vulnerability of older adults to THCs various effects. Participants receive different doses of THC or a placebo through an intravenous infusion lasting 20 minutes. The study uses a randomized, crossover design where each participant receives multiple treatments in separate sessions, including very low and medium doses of THC and a placebo with no THC. The study is conducted under careful monitoring with masking to ensure unbiased results. Throughout the study, participants undergo tests such as the Rey Auditory Verbal Learning Task to assess memory shortly after each drug infusion. Subjective responses are measured repeatedly using a visual analog scale at various time points up to seven hours after infusion start. The study also monitors heart rate and blood pressure to evaluate cardiovascular changes. The entire participation period extends until study completion in 2028, with close observation during and after each infusion session.

Age: 21Years +All GendersPhase 1
1 location
S

Actively Recruiting

Researchers are studying the nicotine threshold doses that smokers with different levels of dependence can detect, find rewarding, and choose to reinforce their smoking behavior. The study aims to determine how well participants can discriminate between nicotine and saline, assess the pleasurable effects of nicotine, and measure their preference for nicotine over saline. This early phase 1 research focuses on smoking addiction and is conducted with healthy adult smokers aged 21 to 59 years. Participants will first attend an Adaptation Session to get familiar with the study procedures. Then, they will complete four Test Days, each testing a different dose of nicotine 0.1, 0.05, 0.025, or 0.0125 mg nicotine per pulse compared to saline. During each Test Day, participants sample both the assigned nicotine dose and saline, complete trials to test their ability to discriminate nicotine from saline, and then choose between nicotine and saline in several choice trials. The nicotine and saline infusions are administered using a pump, and the study uses a double-blind, randomized crossover design. Throughout the study, researchers will evaluate how accurately participants identify nicotine versus saline, measure the subjective pleasurable effects using the Drug Effects Questionnaire, and calculate the percentage of nicotine choices during the choice trials to assess reinforcement. Participants smoking status will be confirmed by urine tests, and health screenings will be performed before participation. The entire study includes multiple visits spread over about 8 weeks, with careful monitoring and assessment of nicotine discrimination and reward responses.

Age: 21Years - 59YearsAll GendersEarly Phase 1
1 location
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
P

Actively Recruiting

Researchers are evaluating the effects of albumin on diuresis in patients with cirrhosis, ascites, and persistent lower extremity edema. This pilot, proof-of-concept, placebo-controlled trial aims to explore how albumin influences sodium excretion, neurohumoral activation, and the risk of acute kidney injury after diuresis in this population. The study is a double-blind, randomized Phase 2 trial sponsored by Anahita Rabiee MD MHS. Participants will receive one dose of either albumin 25 grams infused as 25% albumin or placebo 100 cc of normal saline, followed by at least a 14-day washout period. After the washout, participants will cross over to receive the alternate treatment. This crossover design allows each participant to receive both albumin and placebo during the study. During the study, researchers will measure changes in the fractional excretion of sodium at 6 hours after treatment and monitor neurohormonal markers at 6 and 24 hours. The study involves outpatient participants who will be monitored closely for kidney function, blood pressure, sodium levels, and other safety parameters. Participation will last through both treatment periods plus washout, ensuring thorough assessment of albumins effects compared to placebo.

Age: 18Years +All GendersPhase 2
1 location
O

Actively Recruiting

Chronic pain is a common and serious issue, especially among Veterans who experience it at higher rates than the general population. This research compares two online pain management programs designed to help Veterans with chronic pain improve their daily functioning and quality of life. The study focuses on Acceptance and Commitment Therapy for Chronic Pain ACT-CP delivered digitally, which targets emotional and cognitive aspects of pain and has shown promise in previous research. Participants will be randomly assigned to one of two seven-week online programs. One group will use Veteran ACT for Chronic Pain VACT-CP, guided by an interactive virtual coach called Coach Anne, featuring interactive text conversations, videos, and goal-setting exercises. The other group will participate in Online Pain School, an active control program providing educational videos and behavioral exercises for pain management. Both interventions consist of weekly modules lasting about 15 minutes each. Throughout and after the treatment period, participants will complete surveys at week 7, 3 months, and 6 months to provide feedback and measure outcomes related to pain intensity, functioning, quality of life, psychological flexibility, and satisfaction. Researchers will monitor usability and the impact on mental and physical health, aiming to understand how these programs support Veterans pain management over time.

Age: 18Years +All GendersPhase Not Applicable
3 locations
E

Actively Recruiting

Researchers are studying the safety and immediate effects of different doses of Cannabidiol CBD on pain and opioid craving in people with opioid use disorder OUD who are being treated with buprenorphine. This randomized, placebo-controlled, crossover study involves adults with OUD and chronic non-cancer pain lasting at least six months. The study aims to understand how CBD affects opioid-related outcomes while participants continue their medication-assisted treatment. Participants will attend five visits over about four weeks one screening session followed by four experimental sessions. At each experimental session, before their daily buprenorphine dose, participants will receive one of four oral treatments400 mg CBD, 800 mg CBD, 1200 mg CBD, or a placebo beta carotene solution. The order of these treatments is randomized and spaced by at least 72 hours to reduce carryover effects. Blood samples will be taken at screening and at the end of the medication sessions to measure drug levels. During each experimental session, participants will undergo various laboratory tests assessing safety, drug effects, cognitive and psychomotor function, pain sensitivity, opioid craving, and mood. Researchers will collect data before and multiple times after CBD administration using questionnaires and sensory tests. A follow-up phone call will occur one week after the last session. The study is sponsored by Yale University and includes close monitoring by a physician during sessions to ensure participant safety.

Age: 18Years - 70YearsAll GendersEarly Phase 1
1 location

1-10 of 55

1